论文部分内容阅读
目的 检测婴幼儿哮喘发作期的高凝状态指标，并对肝素的抗凝作用进行临床及实验室评价。方法 测定哮喘患儿治疗前后的活化部分凝血活酶时间（ＡＰＴＴ） 、Ｄ二聚体（ＤＤｉｍｅｒ） 、抗凝血酶Ⅲ（ＡＴⅢ） 活性并进行对比。结果 婴幼儿哮喘发作期ＡＰＴＴ明显缩短，６７－５ ％ 患儿ＤＤｉｍｅｒ 增高。肝素治疗后，患儿治疗组ＡＰＴＴ 较正常对照组明显延长，而患儿对照组改变不明显。治疗前后患儿ＡＴⅢ：Ａ 均＞ ８０ ％ 。治疗组临床症状、体征开始及完全消失的时间均短于对照组，且无出血副作用。结论 婴幼儿哮喘发作期存在高凝状态，肝素雾化吸入辅助治疗是一种有效而安全的方法
Objective To detect the indicators of hypercoagulability in infant asthma attack and to evaluate the clinical and laboratory effects of heparin anticoagulation. Methods The activated partial thromboplastin time (APTT), DDimer and antithrombin Ⅲ (AT Ⅲ) activity in asthmatic children before and after treatment were measured and compared. Results Infant asthma attack APTT was significantly shorter, 67-5% of children with D Dimer increased. After heparin treatment, APTT in children treated group was significantly longer than that in normal control group, while the control group did not change significantly. Before and after treatment in children AT Ⅲ: A> 80%. The clinical symptoms, signs and signs disappeared in the treatment group were shorter than the control group, and no bleeding side effects. Conclusions There is hypercoagulable state in infancy and asthma attack. As an effective and safe method, adjuvant heparin inhalation therapy